Skip to main content
SpringerLink
Log in

Tardive Dyskinesia

  • Chapter
  • First Online:
Movement Disorders Curricula

Abstract

Tardive dyskinesia (TD) is a potentially highly disabling, permanent consequence of antidopaminergic agents used to treat psychotic disorders and nonpsychiatric conditions like nausea and gastroparesis. Several pathophysiological models have been proposed, but alterations in dopaminergic signaling pathways are most implicated. Despite its long history and increasing prevalence, there is currently no standard treatment approach or guideline for physicians confronted with patients that have TD. Since this is an iatrogenic disease, prevention is the best strategy. However, dopaminergic antagonists remain the standard of treatment for many psychiatric conditions, and hence various treatment options have been studied to manage TD. Tetrabenazine (TBZ) and several similar medications are promising drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 149.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AIMS:

Abnormal Involuntary Movement Scale

ATAs:

Atypical antipsychotics

BCAAs:

Branched-chain amino acids

BDNF:

Brain-derived neurotrophic factor

DBS:

Deep brain stimulation

TAs:

Typical antipsychotics

TBZ:

Tetrabenazine

TD:

Tardive dyskinesia

References

  1. Chaudhuri KR, Ondo WG, Logishetty K, Redyy P, Sherman R. Handbook of movement disorders. London: Current Medicine Group; 2009.

    Book  Google Scholar 

  2. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4):463–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement – a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138–48.

    Article  CAS  PubMed  Google Scholar 

  4. Brucke T, Wober C, Podreka I, Wober-Bingol C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1995;15(3):513–8.

    Article  CAS  Google Scholar 

  5. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–80.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry. 2007;12(9):794–5.

    Article  CAS  PubMed  Google Scholar 

  7. Zai CC. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol. 2007;10:639–51.

    Article  CAS  PubMed  Google Scholar 

  8. Tsai HT, North KE, West SL, Poole C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2010;153b(1):57–66.

    CAS  Google Scholar 

  9. Halford J, Mazeika G, Slifer S, Speer M, Saunders AM, Strittmatter WJ, et al. APOE2 allele increased in tardive dyskinesia. Mov Disord. 2006;21(4):540–2.

    Article  PubMed  Google Scholar 

  10. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Muller DJ, Shaikh SA, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res. 2013;47(11):1760–5.

    Article  PubMed  Google Scholar 

  11. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2010;35(5):1155–64.

    Article  CAS  Google Scholar 

  12. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J. 2012;12(6):513–20.

    Article  CAS  PubMed  Google Scholar 

  13. Muller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry. 2013;26(2):144–50.

    Article  PubMed  Google Scholar 

  14. Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, et al. Association between TNF-alpha promoter -308A/G polymorphism and tardive dyskinesian Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):106–10.

    Article  CAS  PubMed  Google Scholar 

  15. Deshpande SN, Varma PG, Semwal P, Rao AR, Bhatia T, Nimgaonkar VL, et al. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet. 2005;15(3):157–8.

    Article  PubMed  Google Scholar 

  16. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28(12):550–3.

    CAS  PubMed  Google Scholar 

  17. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinetic Mov (NY). 2013;3:p.27 http://tremorjournal.org/article/view/161

  18. Schroder J, Bubeck B, Sauer H. D2-dopamine receptor upregulation and treatment response under neuroleptic therapy. Fortschr Neurol Psychiatr. 2000;68 Suppl 1:S42–5.

    PubMed  Google Scholar 

  19. Nyberg S, Nordstrom AL, Halldin C, Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol. 1995;10 Suppl 3:81–5.

    PubMed  Google Scholar 

  20. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49(7):538–44.

    Article  CAS  PubMed  Google Scholar 

  21. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–20.

    Article  CAS  PubMed  Google Scholar 

  22. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2009;34(3):662–71.

    Article  CAS  Google Scholar 

  23. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord Off J Mov Disord Soc. 2012;27(10):1205–15.

    Article  Google Scholar 

  24. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013;7:1329–40.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci Off J Soc Neurosci. 2011;31(44):15727–31.

    Article  CAS  Google Scholar 

  26. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984;309(5966):347–9.

    Article  CAS  PubMed  Google Scholar 

  27. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry Rev Can Psychiatr. 2005;50(9):541–7.

    Article  Google Scholar 

  28. Grimm JW, Chapman MA, Zahm DS, See RE. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse (New York, NY). 2001;39(1):51–7.

    Article  CAS  Google Scholar 

  29. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull. 1999;25(4):731–40.

    Article  CAS  PubMed  Google Scholar 

  30. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci. 2003;17(8):1563–70.

    Article  PubMed  Google Scholar 

  31. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47–62.

    Article  CAS  PubMed  Google Scholar 

  32. Zhang XY, Zhang W-F, Zhou D-F, Chen DC, Xiu MH, Wu H-R, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry. 2012;72(8):700–6.

    Article  CAS  PubMed  Google Scholar 

  33. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331–73.

    Article  CAS  PubMed  Google Scholar 

  34. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300–2.

    Article  CAS  PubMed  Google Scholar 

  35. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509–23.

    Article  CAS  PubMed  Google Scholar 

  36. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):88–91.

    Article  CAS  PubMed  Google Scholar 

  37. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–5.

    Article  CAS  PubMed  Google Scholar 

  38. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51.

    Article  CAS  PubMed  Google Scholar 

  39. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160(6):1117–24.

    Article  PubMed  Google Scholar 

  40. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73(11):1434–8.

    Article  PubMed  Google Scholar 

  41. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients.Eur Arch Psychiatry Clin Neurosci. 1998;248(4):209–11.

    Article  CAS  PubMed  Google Scholar 

  42. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;(2):CD000209.

    Google Scholar 

  43. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615–21.

    Article  PubMed  Google Scholar 

  44. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648–54.

    Article  CAS  PubMed  Google Scholar 

  45. Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–9.

    Article  CAS  PubMed  Google Scholar 

  46. van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord Off J Mov Disord Soc. 2006;21(8):1276–7.

    Article  Google Scholar 

  47. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord Off J Mov Disord Soc. 2006;21(8):1219–21.

    Article  Google Scholar 

  48. Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012;315(1–2):137–40.

    Article  CAS  PubMed  Google Scholar 

  49. Castro F, Carrizo E, Prieto de Rincon D, Rincon D, Rincon CA, Asian T, Medina-Leendertz S, et al. Effectiveness of melatonin in tardive dyskinesia. Invest Clin. 2011;52(3):252–60.

    PubMed  Google Scholar 

  50. Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother. 2003;37(7–8):1128–31.

    Article  PubMed  Google Scholar 

  51. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011(11):CD000206.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Texas, Houston, 6431 Fannin street, MSB 7.044, Houston, TX, 77030, USA

    Sweta Goel MBBS

  2. Methodist Neurological Instituter, Houston, TX, USA

    William Ondo MD (Director of Movement disorders)

Authors
  1. Sweta Goel MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Ondo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William Ondo MD .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Transilvania University, Brasov, Romania

    Cristian Falup-Pecurariu

  2. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Lisbon, Portugal

    Joaquim Ferreira

  3. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain

    Pablo Martinez-Martin

  4. Centre of Excellence, King’s College London, National Parkinson Foundation Centre of Excellence King’s College, London, United Kingdom

    Kallol Ray Chaudhuri

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Wien

About this chapter

Cite this chapter

Goel, S., Ondo, W. (2017). Tardive Dyskinesia. In: Falup-Pecurariu, C., Ferreira, J., Martinez-Martin, P., Chaudhuri, K. (eds) Movement Disorders Curricula. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1628-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1628-9_27

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1627-2

  • Online ISBN: 978-3-7091-1628-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation